This video is the first in a five-part series that focuses on making sense of multiple myeloma treatment based upon the newly obtained input from the American Society Hematology (ASH) in Orlando, FL.

Download Slides

Topics include:


with an educational grant from:
Amgen Oncology, Takeda Oncology, Janssen Oncology


Previous Post
Frontline Therapy: IMWG Conference Series ASH 2019
Next Post
Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dex in Unfit and Frail NDMM Patients

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.